Robert Motzer
罗伯特·莫策尔
MD
Jack and Dorothy Byrne Chair in Clinical Oncology临床肿瘤学杰克与多萝西·伯恩讲席教授
👥Biography 个人简介
Robert Motzer is a foundational figure in kidney cancer oncology at MSKCC, credited with establishing sunitinib as first-line therapy and co-leading CheckMate 214. His decades-long career has produced seminal advances in metastatic RCC treatment and prognostic classification.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Sunitinib as First-Line RCC Therapy
Led the pivotal phase III trial establishing sunitinib superiority over interferon-alfa, making it the first approved targeted therapy for first-line metastatic renal cell carcinoma worldwide.
MSKCC Prognostic Model
Developed the widely used MSKCC risk stratification model for metastatic RCC, enabling risk-adapted treatment selection and serving as the basis for clinical trial stratification globally.
Representative Works 代表性著作
Sunitinib versus Interferon Alfa in Metastatic Renal Cell Carcinoma
New England Journal of Medicine (2007)
Phase III trial establishing sunitinib as the new standard first-line therapy for metastatic RCC.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal Cell Carcinoma
New England Journal of Medicine (2018)
CheckMate 214 co-led pivotal trial demonstrating improved OS with dual checkpoint blockade in mRCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Brian I. Rini
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Robert J. Motzer
Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Dana-Farber Cancer Institute, Harvard Medical School
Jonathan Rosenberg
Memorial Sloan Kettering Cancer Center
关注 罗伯特·莫策尔 的研究动态
Follow Robert Motzer's research updates
留下邮箱，当我们发布与 Robert Motzer（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment